Valeant Pharmaceuticals International has raised C$750m ($591.37m) through the private placement of senior secured notes.

Due 2025, the notes carry a rate of 5.5%.

The US-based pharmaceutical company plans to use the funds to repay a part of its outstanding loan and for related expenses.

UK-based pharmaceutical products manufacturer Hikma Pharmaceuticals has acquired six products from German pharmaceutical company Boehringer Ingelheim for €3m ($3.49m).

“Chinese pharmaceutical company Yabao Pharmaceutical Group plans to raise CNY500m ($75.29m) through the private placement of corporate bonds.”

The products acquired include Alupent, Gastrozepin, Paracefan, Partusisten and Spiropent in Germany and Mantadan in Italy.

Chinese pharmaceutical company Yabao Pharmaceutical Group plans to raise CNY500m ($75.29m) through the private placement of corporate bonds.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Synergy Pharmaceuticals has announced a public offering of 21 million shares of its common stock priced at $2.58 a share to raise $56m.

The US-based biopharmaceutical company plans to use the funds towards general corporate purposes, working capital, and capital expenditures.